Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Monte Rosa Therapeutics Q3 2026 Results: Turns Profitable, Net Income $3.06M

Monte Rosa Therapeutics reported a net loss of $84.8 million for the nine months ended September 30, 2026, compared to a net income of $7.5 million in the prior year period, primarily due to lower collaboration revenue. The company significantly strengthened its balance sheet through an underwritten public offering that raised $323.8 million, ending the period with $577.7 million in cash, cash equivalents, and marketable securities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue54.412.8
Profit before tax3.8-30.3
Net income3.1-27.1

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+325.8%
Operating margin-3.6%
Source

10-Q filed with the SEC, NASDAQ: GLUE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Monte Rosa Therapeutics, Inc.: key numbers

Share price
$9.07Close, Nov 17
Market cap
$775M
Shares outstanding
85.45MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Monte Rosa Therapeutics, Inc.

All →
7:08 AM ET 8-K
Financial Results

Monte Rosa Therapeutics Financial Results

Monte Rosa Therapeutics reported Q3 2026 financial results, highlighting a cash position of $582.6 million and $87.5 million in milestone payments triggered by Novartis initiating Phase 2 studies for MRT-6160. The company also announced positive Phase 1 data for MRT-8102 in cardiovascular disease and the initiation of multiple Phase 2 clinical trials across its pipeline.

Counterparty
Novartis
Term
3 months

“The last quarter marks a tremendously important step forward for our clinical portfolio, with a positive readout from the GFORCE-1 study of MRT-8102, the initiation of Phase 2 development for MRT-2359, and the advancement of our partnered VAV1 program into two Phase 2 studies.”

Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics

“We are particularly excited about the opportunity in gout, where there is a substantial unmet need for effective flare prevention that is well tolerated with prolonged use.”

Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics
7:39 AM ET 8-K
Clinical Trial Data

Monte Rosa Therapeutics Clinical Trial Data

Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, a NEK7-directed molecular glue degrader for inflammatory diseases. The GFORCE-1 study in 108 subjects showed 80-90% NEK7 degradation and normalization of key ASCVD pathogenic drivers with a favorable safety profile, supporting the planned initiation of multiple Phase 2 studies in coronary artery disease, gout, and hidradenitis suppurativa.

Earnings call
Oct 1, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.